TIAA CREF Investment Management LLC lessened its position in shares of NewLink Genetics Corporation (NASDAQ:NLNK) by 0.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 93,963 shares of the biotechnology company’s stock after selling 77 shares during the period. TIAA CREF Investment Management LLC owned about 0.32% of NewLink Genetics Corporation worth $691,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Northwest Wealth Management LLC grew its holdings in NewLink Genetics Corporation by 3.1% during the 2nd quarter. Northwest Wealth Management LLC now owns 58,022 shares of the biotechnology company’s stock worth $426,000 after acquiring an additional 1,740 shares in the last quarter. Prudential Financial Inc. acquired a new position in NewLink Genetics Corporation during the 1st quarter worth approximately $443,000. Bank of America Corp DE grew its holdings in NewLink Genetics Corporation by 361.8% during the 1st quarter. Bank of America Corp DE now owns 31,911 shares of the biotechnology company’s stock worth $769,000 after acquiring an additional 25,001 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in NewLink Genetics Corporation by 34.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 86,143 shares of the biotechnology company’s stock worth $2,076,000 after acquiring an additional 22,165 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in NewLink Genetics Corporation by 21.0% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 86,369 shares of the biotechnology company’s stock worth $2,082,000 after acquiring an additional 14,975 shares in the last quarter. Institutional investors own 45.31% of the company’s stock.

WARNING: “TIAA CREF Investment Management LLC Has $691,000 Holdings in NewLink Genetics Corporation (NLNK)” was originally published by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/11/15/tiaa-cref-investment-management-llc-has-691000-holdings-in-newlink-genetics-corporation-nlnk.html.

In related news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of NewLink Genetics Corporation stock in a transaction dated Friday, October 6th. The stock was acquired at an average price of $10.25 per share, for a total transaction of $7,999,991.75. Following the transaction, the insider now owns 7,857,732 shares of the company’s stock, valued at $80,541,753. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 13.70% of the stock is currently owned by insiders.

NLNK has been the subject of several analyst reports. Cantor Fitzgerald reiterated a “buy” rating and set a $26.00 price target on shares of NewLink Genetics Corporation in a report on Thursday, November 2nd. Zacks Investment Research upgraded shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating and set a $10.00 price target for the company in a report on Tuesday, November 7th. Robert W. Baird upgraded shares of NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $8.00 to $22.00 in a report on Friday, September 8th. Stifel Nicolaus boosted their price target on shares of NewLink Genetics Corporation from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. Finally, Jefferies Group LLC reduced their price objective on shares of NewLink Genetics Corporation from $26.00 to $25.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $23.43.

Shares of NewLink Genetics Corporation (NLNK) opened at $8.36 on Wednesday. NewLink Genetics Corporation has a 12-month low of $5.90 and a 12-month high of $25.17.

NewLink Genetics Corporation Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Institutional Ownership by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.